Vir Biotechnology
🇺🇸United States
- Country
- 🇺🇸United States
- Ownership
- Public
- Established
- 2016-04-07
- Employees
- 587
- Market Cap
- -
- Website
- http://www.vir.bio
- Introduction
Vir Biotechnology, Inc. operates as a clinical-stage immunology company that focuses on combining immunologic insights with cutting-edge technologies to treat and prevent serious infectious diseases. The firm's technology platforms include antibody, T cell, innate immunity and siRNA, which are designed to stimulate and enhance the immune system by exploiting critical observations of natural immune processes. The company was founded by Robert Taylor Nelsen, Klaus Frueh, Jay Parrish, Lawrence Corey, and Louis Picker in April 7, 2016 and is headquartered in San Francisco, CA.
Vir Biotechnology, Inc. Announces Executive Appointments
Vir Biotechnology appoints Jason O'Byrne as EVP and CFO, effective October 2, 2024, and Brent Sabatini as principal accounting officer, effective October 1, 2024.
Vir Biotechnology Names Jason O'Byrne as Chief Financial Officer
Vir Biotechnology appoints Jason O’Byrne as CFO, effective October 2, 2024. O’Byrne brings over 20 years of finance and operations experience, previously serving as CFO at Caribou Biosciences and Senior VP of Finance at Audentes Therapeutics.
Vir Biotechnology Enhances Portfolio with Sanofi Deal and Executive Appointments
Vir Biotechnology finalized a global licensing deal with Sanofi for three clinical-stage T-cell engagers and a protease-cleavable masking platform, paying $100 million initially and potentially over $1.8 billion, plus royalties. The deal also transfers key Sanofi employees to Vir. Vir appointed Jason O’Byrne as CFO and Brent Sabatini as principal accounting officer.
Vir Biotechnology Appoints Jason O'Byrne as Chief Financial Officer
Vir Biotechnology appoints Jason O'Byrne as CFO, effective October 2, 2024, bringing over 20 years of finance and operations experience from Caribou Biosciences, Audentes Therapeutics, and Genentech. His expertise in capital allocation, corporate strategy, and operational execution aims to support Vir's expansion into oncology and continued work in infectious diseases.
Vir Biotechnology closes Sanofi licence deal for T-cell engagers
Vir Biotechnology has finalized an exclusive worldwide license agreement with Sanofi, gaining access to clinical-stage T-cell engagers (TCEs) and the PRO-XTEN masking platform for oncology and infectious disease. The deal includes three TCEs targeting distinct cancer markers and leverages the PRO-XTEN technology to enhance therapeutic index by selectively activating within the tumor microenvironment.
Vir Biotechnology secures Sanofi cancer drug licenses
Vir Biotechnology finalized a licensing deal with Sanofi, gaining exclusive rights to three cancer therapies using Sanofi's PRO-XTENTM platform. The deal includes SAR446309, SAR446329, and SAR446368, targeting HER2+ tumors, metastatic castration-resistant prostate cancer, and EGFR-expressing tumors, respectively. Vir's CEO, Marianne De Backer, is optimistic about these therapies' potential. Financial terms were undisclosed, but the acquisition is pivotal for Vir's oncology and infectious disease portfolio expansion.
Vir Biotechnology Announces Closing of Exclusive Worldwide License Agreement With ...
Form includes dropdowns for selecting state, zip code, and country, with California and United States pre-selected.
Vir Biotechnology Announces Closing of Exclusive Worldwide License Agreement With Sanofi
Vir Biotechnology closed an exclusive worldwide license agreement with Sanofi, gaining three clinical-stage masked T-cell engagers (TCEs) for cancer treatment and the PRO-XTEN masking platform for oncology and infectious disease. The agreement includes SAR446309 for HER2+ tumors, SAR446329 for prostate cancer, and SAR446368 for EGFR-expressing tumors, with clinical studies to commence. Key Sanofi employees with TCE expertise will join Vir, enhancing its drug discovery capabilities.
© Copyright 2024. All Rights Reserved by MedPath